212 related articles for article (PubMed ID: 38238581)
1. Multi-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency.
Xu R; Wang Y; Kuang Y
Sci Rep; 2024 Jan; 14(1):1651. PubMed ID: 38238581
[TBL] [Abstract][Full Text] [Related]
2. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
Pan W; Liu X; Liu S
Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085
[TBL] [Abstract][Full Text] [Related]
3. m5CRegpred: Epitranscriptome Target Prediction of 5-Methylcytosine (m5C) Regulators Based on Sequencing Features.
He Z; Xu J; Shi H; Wu S
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456483
[TBL] [Abstract][Full Text] [Related]
4. ALYREF-mediated RNA 5-Methylcytosine modification Promotes Hepatocellular Carcinoma Progression Via Stabilizing EGFR mRNA and pSTAT3 activation.
Nulali J; Zhang K; Long M; Wan Y; Liu Y; Zhang Q; Yang L; Hao J; Yang L; Song H
Int J Biol Sci; 2024; 20(1):331-346. PubMed ID: 38164181
[TBL] [Abstract][Full Text] [Related]
5. 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma.
Liu T; Hu X; Lin C; Shi X; He Y; Zhang J; Cai K
Ann Transl Med; 2022 Mar; 10(5):259. PubMed ID: 35402591
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing.
Zhang Z; Cao C; Zhou CL; Li X; Miao C; Shen L; Singla RK; Lu X
Transl Oncol; 2023 Oct; 36():101741. PubMed ID: 37523897
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract][Full Text] [Related]
8. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
9. Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.
Tan X; Cai Z; Chen G; Cai C; Chen J; Liang Y; Zhuo Y; Liu J; Huang L; Ouyang B; Wei Y; Jia Z; Deng J; Zhong W; Lu J
Discov Oncol; 2023 May; 14(1):62. PubMed ID: 37155024
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of m5C regulatory genes in hepatocellular carcinoma.
Yang X; Yang F; Lan L; Wen N; Li H; Sun X
Front Genet; 2022; 13():972043. PubMed ID: 36105093
[No Abstract] [Full Text] [Related]
11. Integrated single-cell and spatial transcriptomic analysis reveals YBX1 drives immune regulation in GBM progression.
Ge Y; Weng H; Sun Y; Wu M
Heliyon; 2024 Apr; 10(8):e29451. PubMed ID: 38628755
[TBL] [Abstract][Full Text] [Related]
12. ALYREF (Aly/REF export factor): A potential biomarker for predicting cancer occurrence and therapeutic efficacy.
Zhao Y; Xing C; Peng H
Life Sci; 2024 Feb; 338():122372. PubMed ID: 38135116
[TBL] [Abstract][Full Text] [Related]
13. Identification of ALYREF in pan cancer as a novel cancer prognostic biomarker and potential regulatory mechanism in gastric cancer.
Yuan Y; Fan Y; Tang W; Sun H; Sun J; Su H; Fan H
Sci Rep; 2024 Mar; 14(1):6270. PubMed ID: 38491127
[TBL] [Abstract][Full Text] [Related]
14. m5C methylation modification guides the prognostic value and immune landscapes in acute myeloid leukemia.
Liu Y; Chen Y; Cai M; Hong Y; Wu X; Li S
Aging (Albany NY); 2023 Sep; 15(18):9858-9876. PubMed ID: 37751592
[TBL] [Abstract][Full Text] [Related]
15. Gene signatures of m5C regulators may predict prognoses of patients with head and neck squamous cell carcinoma.
Xue M; Shi Q; Zheng L; Li Q; Yang L; Zhang Y
Am J Transl Res; 2020; 12(10):6841-6852. PubMed ID: 33194076
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
17. 5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma.
Chen C; Chen LY; Zhang JX; Xu HG
Curr Oncol; 2022 Dec; 30(1):559-574. PubMed ID: 36661693
[TBL] [Abstract][Full Text] [Related]
18. m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
Chen B; Xi Y; Zhao J; Hong Y; Tian S; Zhai X; Chen Q; Ren X; Fan L; Xie X; Jiang C
Front Immunol; 2022; 13():1049435. PubMed ID: 36532062
[TBL] [Abstract][Full Text] [Related]
19. Exploration of Potential Roles of m5C-Related Regulators in Colon Adenocarcinoma Prognosis.
Huang Y; Huang C; Jiang X; Yan Y; Zhuang K; Liu F; Li P; Wen Y
Front Genet; 2022; 13():816173. PubMed ID: 35281843
[No Abstract] [Full Text] [Related]
20. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
